The PBD Biotech international management team brings together expertise in diagnostics, clinical and veterinary science, disease management and policy.
About PBD Biotech
PBD Biotech is developing Actiphage TB to achieve the goals of the WHO End TB strategy.
- Co-founded in 2014 as academic spin-out
- First clinical study initiated 2017
- Jane Theaker, Chief Executive Officer since December, 2021
- Actiphage patents published:
- 2015 Mycobacteria Detection using bacteriophages
- 2020 Methods relating to Tuberculosis (the transition from incipient to active infection in LTBI patients)
- Clinical research
- 2020 Actiphage Proof-of-Concept (POC) Leicester 1, published CID
- 2022 Actiphage POC Leicester 2, presented ECCMID 2022
Actiphage is industry recognised:
2020 Actiphage proof-of-Concept Leicester 1, published CID2022
Actiphage proof-of-concept Leicester 2, presented ECCMID 2022
Related content
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local...
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a...
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is...
